• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

The study for elucidating the mechanisms of HIV-1's EFdA resistance.

Research Project

Project/Area Number 17K15710
Research Category

Grant-in-Aid for Young Scientists (B)

Allocation TypeMulti-year Fund
Research Field Virology
Research InstitutionTohoku University (2018)
National Center for Global Health and Medicine (2017)

Principal Investigator

Hayashi Hironori  東北大学, 医学系研究科, 助教 (00752916)

Project Period (FY) 2017-04-01 – 2019-03-31
Project Status Completed (Fiscal Year 2018)
Budget Amount *help
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2018: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2017: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
KeywordsHIV / 逆転写酵素 / EFdA / 薬剤耐性化 / HIV-1 / HIV-1 / 結晶構造解析 / 創薬
Outline of Final Research Achievements

EFdA was developed as a HIV-1 reverse transcriptase (RT) inhibitor and has been under the clinical trial. In this study, we purified the reverse transcriptase from EFdA resistant HIV-1 variants (RT-EFdA-R) and screened the crystallization conditions. Additionally, we employed the analysis by molecular dynamics to determine the EFdA resistant mechanisms of RT. As the result, an amino acid mutation (M184V) would decreas Van der Waals (VdW) interactions between EFdA and RT-EFdA-R. Thus, the M184V would decrease binding affinity of EFdA. However, EFdA keep strong interactions with F160, which is an amino acid locating at the cavity close to the active center of RT with and without M184V substitution. Notably, the introduction of amino acid mutation, F160A, eliminate growth ability of HIV-1. Thus, HIV-1 hardly introduced the mutation. This was the reason for the high genetic barrier of EFdA. These data shed light on developing the novel RT inhibitors.

Academic Significance and Societal Importance of the Research Achievements

EFdAは、HIV-1に対する抗ウイルス療法を1日1回から1週間又は1か月に1回へと変える可能性を有している。また、このような化合物はHIV-1の二次感染を予防する為にも非常に有用でありその社会貢献度は計り知れない。この様に医療、社会、国民衛生に重要な化合物に対してHIV-1が耐性を獲得する機序を詳細に解析する事は、医療の面からも重要であり、また、EFdAがハイジェネティックバリアを発揮する機序は新規化合物の開発に資するため学術的にも非常に有用である。

Report

(3 results)
  • 2018 Annual Research Report   Final Research Report ( PDF )
  • 2017 Research-status Report
  • Research Products

    (10 results)

All 2018 2017

All Journal Article (9 results) (of which Int'l Joint Research: 9 results,  Peer Reviewed: 9 results,  Open Access: 6 results) Book (1 results)

  • [Journal Article] Design and Synthesis of Potent HIV-1 Protease Inhibitors Containing Bicyclic Oxazolidinone Scaffold as the P2 Ligands: Structure-Activity Studies and Biological and X-ray Structural Studies.2018

    • Author(s)
      Ghosh AK, Williams JN, Ho RY, Simpson HM, Hattori SI, Hayashi H, Agniswamy J, Wang YF, Weber IT, Mitsuya H.
    • Journal Title

      J Med Chem.

      Volume: 61(21) Issue: 21 Pages: 9722-9737

    • DOI

      10.1021/acs.jmedchem.8b01227

    • Related Report
      2018 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] The High Genetic Barrier of EFdA/MK-8591 Stems from Strong Interactions with the Active Site of Drug-Resistant HIV-1 Reverse Transcriptase2018

    • Author(s)
      Takamatsu Yuki、Das Debananda、Kohgo Satoru、Hayashi Hironori、Delino Nicole S.、Sarafianos Stefan G.、Mitsuya Hiroaki、Maeda Kenji
    • Journal Title

      Cell Chemical Biology

      Volume: 25 Issue: 10 Pages: 1268-1278

    • DOI

      10.1016/j.chembiol.2018.07.014

    • Related Report
      2018 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] GRL-079, a novel P2-Tp-THF-C5-alkylamine- and P2' -Abt-containing HIV-1 protease inhibitor, is extremely potent against multi-drug-resistant HIV-1 variants including HIVDRVRp51 and has a high genetic barrier against the emergence of resistant variants.2018

    • Author(s)
      Delino NS, Aoki M, Hayashi H, Hattori SI, Chang SB, Takamatsu Y, Martyr CD, Das D, Ghosh AK, Mitsuya H.
    • Journal Title

      Antimicrob Agents Chemother.

      Volume: 62(5) Issue: 5 Pages: 02060-17

    • DOI

      10.1128/aac.02060-17

    • Related Report
      2018 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Mechanism of Darunavir (DRV)'s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance.2018

    • Author(s)
      Aoki M, Das D, Hayashi H, Aoki-Ogata H, Takamatsu Y, Ghosh AK, Mitsuya H.
    • Journal Title

      MBio.

      Volume: 9(2) Issue: 2

    • DOI

      10.1128/mbio.02425-17

    • Related Report
      2018 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] HIV-1 with HBV-associated Q151M substitution in RT becomes highly susceptible to entecavir: structural insights into HBV-RT inhibition by entecavir.2018

    • Author(s)
      Yasutake Y, Hattori SI, Hayashi H, Matsuda K, Tamura N, Kohgo S, Maeda K, Mitsuya H.
    • Journal Title

      Sci Rep.

      Volume: 8(1) Issue: 1 Pages: 1624-1624

    • DOI

      10.1038/s41598-018-19602-9

    • Related Report
      2018 Annual Research Report 2017 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Raltegravir blocks the infectivity of red-fluorescent-protein (mCherry)-labeled HIV-1 JR-FL in the setting of post-exposure prophylaxis in NOD/SCID/Jak3 ?/? mice transplanted with human PBMCs2018

    • Author(s)
      Ogata-Aoki Hiromi、Higashi-Kuwata Nobuyo、Hattori Shin-ichiro、Hayashi Hironori、Danish Matthew、Aoki Manabu、Shiotsu Chiemi、Hashiguchi Yumi、Hamada Akinobu、Kobayashi Hisataka、Ihn Hironobu、Okada Seiji、Mitsuya Hiroaki
    • Journal Title

      Antiviral Research

      Volume: 149 Pages: 78-88

    • DOI

      10.1016/j.antiviral.2017.09.003

    • Related Report
      2018 Annual Research Report 2017 Research-status Report
    • Peer Reviewed / Int'l Joint Research
  • [Journal Article] A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potency.2017

    • Author(s)
      Aoki M, Hayashi H, Rao KV, Das D, Higashi-Kuwata N, Bulut H, Aoki-Ogata H, Takamatsu Y, Yedidi RS, Davis DA, Hattori SI, Nishida N, Hasegawa K, Takamune N, Nyalapatla PR, Osswald HL, Jono H, Saito H, Yarchoan R, Misumi S, Ghosh AK, Mitsuya H.
    • Journal Title

      Elife

      Volume: 6

    • DOI

      10.7554/elife.28020

    • Related Report
      2017 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Early phase dynamics of traceable mCherry fluorescent protein-carrying HIV-1 infection in human peripheral blood mononuclear cells-transplanted NOD/SCID/Jak3 -/- mice2017

    • Author(s)
      Higashi-Kuwata Nobuyo、Ogata-Aoki Hiromi、Hattori Shin-ichiro、Hayashi Hironori、Danish Matthew、Aoki Manabu、Shiotsu Chiemi、Kawamura Tatsuyoshi、Ihn Hironobu、Kobayashi Hisataka、Okada Seiji、Mitsuya Hiroaki
    • Journal Title

      Antiviral Research

      Volume: 144 Pages: 83-92

    • DOI

      10.1016/j.antiviral.2017.03.027

    • Related Report
      2017 Research-status Report
    • Peer Reviewed / Int'l Joint Research
  • [Journal Article] Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants.2017

    • Author(s)
      Ghosh AK, Rao KV, Nyalapatla PR, Osswald HL, Martyr CD, Aoki M, Hayashi H, Agniswamy J, Wang YF, Bulut H, Das D, Weber IT, Mitsuya H.
    • Journal Title

      J Med Chem.

      Volume: 60(10) Issue: 10 Pages: 4267-4278

    • DOI

      10.1021/acs.jmedchem.7b00172

    • Related Report
      2017 Research-status Report
    • Peer Reviewed / Int'l Joint Research
  • [Book] HIV感染症とAIDSの治療2017

    • Author(s)
      林 宏典, 満屋 裕明
    • Total Pages
      8
    • Publisher
      株式会社メディカルレビュー社
    • ISBN
      9784779219023
    • Related Report
      2017 Research-status Report

URL: 

Published: 2017-04-28   Modified: 2020-03-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi